We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Gene Therapy Treatment Extends Life of Mice Severely Affected by Muscular Dystrophy

By LabMedica International staff writers
Posted on 11 Oct 2015
An alternative gene therapy approach was used to successfully treat a mouse model of Duchenne muscular dystrophy (DMD).

DMD is caused by mutations in the gene that encodes the protein dystrophin and the subsequent disruption of the dystrophin-associated protein complex (DAPC). More...
The disease effects about one of every 3,500 boys whose muscle function is so degraded that they die usually before they reach the age of 30.

To develop methods for treating this syndrome, investigators at Ohio State University (Columbus, USA) chose to work with mice deficient for dystrophin and utrophin, (mdx/utrn−/−) that die between six and 20 weeks of age because of severe muscle weakness, pronounced growth retardation, and kyphosis rather than the more frequently used dmx model whose animals are clinically normal despite lacking dystrophin.

Dystrophin deficiency has been definitively established as one of the root causes of the general class of myopathies collectively referred to as muscular dystrophy. In normal muscle cells, utrophin is located at the neuromuscular synapse and myotendinous junctions. It is necessary for normal membrane maintenance, and for the clustering of the acetylcholine receptor.

The investigators evaluated an alternative to dystrophin replacement by overexpressing the ITGA7 (integrin, alpha 7) gene using adeno-associated virus (AAV) delivery. ITGA7 is a laminin receptor in skeletal muscle that, like the dystrophin–glycoprotein complex, links the extracellular matrix to the internal actin cytoskeleton. ITGA7 is expressed in DMD patients and its overexpression does not elicit an immune response.

In the current study, five to seven day-old mice deficient for dystrophin and utrophin, (mdx/utrn−/−)were treated with the ITGA7 gene delivered via the AAV carrier. Results published in the August 11, 2015, online edition of the journal Human Gene Therapy revealed that by eight weeks following ITGA7 injection, there was widespread expression of the gene at the sarcolemma of multiple muscles. The increased expression of ITGA7 significantly extended longevity and reduced common features of the mdx/utrn−/− mouse, including kyphosis. Overexpression of alpha7 expression protected against loss of force following contraction-induced damage, and increased specific force in the diaphragm and EDL (extensor digitorum longus) muscles eight weeks after gene transfer.

Mice of the mdx/utrn−/− line usually die between six to 20 weeks of age, but gene transfer of alpha7 extended longevity by more than 10 weeks.

Related Links:

Ohio State University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.